BiotechTube
neuroloop

neuroloop

Freiburg, Germany· Est.
neuroloop.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

Neuroloop is an early-stage, privately-held medical device spin-off from the University of Freiburg, developing a closed-loop implantable neuromodulation system. Its proprietary cuff electrode technology aims to enable selective stimulation of specific fibers within the vagus nerve, a significant advancement over existing non-selective approaches. The company is strategically backed by B. Braun's surgical division, Aesculap AG, and is positioned to address major unmet needs in autonomic disorders, beginning with hypertension. Neuroloop represents a convergence of academic research, clinical expertise, and industrial partnership in the MedTech hub of Freiburg.

CardiovascularNeuroscience

Technology Platform

A closed-loop implantable neuromodulation system featuring a proprietary multi-contact cuff electrode designed for selective stimulation of specific fiber types within the vagus nerve.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The primary opportunity is addressing the large, underserved market of treatment-resistant hypertension with a novel, device-based solution.
Success here would validate a platform technology capable of expanding into other major autonomic disorders mediated by the vagus nerve, such as heart failure, inflammatory diseases, and metabolic conditions, representing a multi-billion dollar market potential in bioelectronic medicine.

Risk Factors

Key risks include the unproven clinical efficacy and safety of the selective stimulation approach in humans, significant regulatory hurdles for a novel Class III implantable device, and intense competition from both pharmaceutical and other device-based therapies (e.g., renal denervation).
Execution risk in developing a reliable, long-term implant and securing adequate funding are also critical.

Competitive Landscape

Neuroloop competes in the neuromodulation and device-based hypertension therapy space. Direct competitors include companies developing renal denervation systems (e.g., Medtronic, Recor Medical, Boston Scientific). In bioelectronic VNS, it faces established players with non-selective systems (e.g., LivaNova for epilepsy/depression) and newer entrants targeting inflammation. Neuroloop's key differentiator is its focus on selective, closed-loop stimulation for autonomic control.

More companies in Neuroscience & CNS →More companies in Germany →